We also confirmed that CDC25A inhibition could increase the sensitivity of melanoma to doxorubicin in vitro, suggesting that CDC25A may be a potential synthetic target for doxorubicin treatment in melanoma. This evidence concerns the gene CDC25A and melanoma.